Treatment Initiation and Supportive Care Processes

EP: 1.Introduction and Overview of Multiple Myeloma

EP: 2.Evaluation and Diagnosis of Multiple Myeloma

EP: 3.Role of the Care Partner

EP: 4.Patient Perspective: Diagnosis of Multiple Myeloma

EP: 5.Treatment of Multiple Myeloma

Now Viewing

EP: 6.Treatment Initiation and Supportive Care Processes

When preparing patients with multiple myeloma to begin treatment, health care providers focus heavily on education and support. The initial diagnosis can be overwhelming, and patients are often unfamiliar with the complexity of the 4-drug regimen commonly used as first-line therapy. Providers assess each patient’s understanding of their diagnosis and gradually introduce treatment-related information. This includes thorough explanations of each medication, its purpose, method of administration, and potential adverse effects. To aid comprehension and reduce confusion, patients are often given a summary sheet that outlines the treatment plan and drug details, helping them track what to expect throughout the course of therapy.

Patients are also informed about the logistics of treatment, such as the need for weekly clinic visits for blood work and infusions, as well as the oral medications they’ll need to manage at home. Addressing the practical and emotional impact of this schedule is key, as patients frequently wonder how treatment will affect their daily lives. Providers emphasize the importance of getting reliable information directly from the care team rather than relying on internet searches, which can be misleading or frightening. Trusted resources and patient education tools are shared to provide clarity and reduce anxiety.

Supportive care is another critical aspect of the treatment plan. Because myeloma patients are immunocompromised, they are often prescribed preventive medications. These include antiviral drugs such as acyclovir to guard against shingles and aspirin to lower the risk of blood clots associated with immunomodulatory drugs like lenalidomide or pomalidomide. Patients are also advised to monitor for symptoms of complications and communicate regularly with their care team. In some cases, intravenous immunoglobulin is administered to boost the immune system. Altogether, these measures aim to reduce adverse effects, enhance safety, and help patients feel empowered during their treatment journey.